The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype

Diabetologia

Volumn 60, Issue 9, 2017, Pages 1801-1812

  Vinué, Ángela ^a   Navarro, Jorge ^a,b,c   Herrero Cervera, Andrea ^a   García Cubas, Marta ^a   Andrés Blasco, Irene ^a   Martínez Hervás, Sergio ^a,b,d   Real, José T ^a,b,d   Ascaso, Juan F ^a,b,d   González Navarro, Herminia ^a,d  

^a Instituto Universitario IVI INCLIVA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Atherosclerosis; GLP 1; Inflammation; Macrophage; STAT

Indexed keywords

ARGINASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIRAGLUTIDE; LIXISENATIDE; STAT1 PROTEIN; STAT3 PROTEIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BLOOD PRESSURE; CELLS; CONTROLLED STUDY; EXPERIMENTAL MODEL; GLUCOSE METABOLISM; IN VITRO STUDY; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; COMPLICATION; DRUG EFFECT; INFLAMMATION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; MICE; PEPTIDES; STAT3 TRANSCRIPTION FACTOR;

EID: 85020702776     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4330-3     Document Type: Article

References (40)

1. Bornfeldt KE (2015) Uncomplicating the macrovascular complications of diabetes: the 2014 Edwin Bierman award lecture. Diabetes 64:2689–2697
2. Libby P, Pasterkamp G (2016) Requiem for the ʻvulnerable plaque. Eur Heart J 36:2984–2987
3. Baumgartl J, Baudler S, Scherner M et al (2006) Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metab 3:247–256
4. Gonzalez-Navarro H, Vila-Caballer M, Pastor MF et al (2007) Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolemia in apolipoprotein E-null mice. Front Biosci 12:2291–2298
5. Han S, Liang CP, DeVries-Seimon T et al (2006) Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab 3:257–266
6. Martinez-Hervas S, Vinue A, Nunez L et al (2014) Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis. Cardiovasc Res 103:324–336
7. van Dijk RA, Duinisveld AJ, Schaapherder AF et al (2015) A change in inflammatory footprint precedes plaque instability: a systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis. J Am Heart Assoc 4:e001403
8. Maurovich-Horvat P, Ferencik M, Voros S, Merkely B, Hoffmann U (2014) Comprehensive plaque assessment by coronary CT angiography. Nat Rev Cardiol 11:390–402
9. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153–165
10. Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819–837
11. Wohlfart P, Linz W, Hubschle T et al (2013) Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med 11:84
12. Tashiro Y, Sato K, Watanabe T et al (2014) A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 54:19–26
13. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
14. Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257
15. Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS (2003) Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 307:490–496
16. Werner U, Haschke G, Herling AW, Kramer W (2010) Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 164:58–64
17. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530–2539
18. Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975–983
19. Noyan-Ashraf MH, Shikatani EA, Schuiki I et al (2013) A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127:74–85
20. Martorell S, Hueso L, Gonzalez-Navarro H, Collado A, Sanz MJ, Piqueras L (2016) Vitamin D receptor activation reduces angiotensin-ii-induced dissecting abdominal aortic aneurysm in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 36:1587–1597
21. Gonzalez-Navarro H, Nong Z, Amar MJ et al (2004) The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice. J Biol Chem 279:45312–45321
22. Gonzalez-Navarro H, Vinue A, Sanz MJ et al (2013) Increased dosage of Ink4/Arf protects against glucose intolerance and insulin resistance associated with aging. Aging Cell 12:102–111
23. Vinue A, Andres-Blasco I, Herrero-Cervera A et al (2015) Ink4/Arf locus restores glucose tolerance and insulin sensitivity by reducing hepatic steatosis and inflammation in mice with impaired IRS2-dependent signalling. Biochim Biophys Acta 1852:1729–1742
24. Gonzalez-Navarro H, Abu Nabah YN, Vinue A et al (2010) p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol 55:2258–2268
25. Andres-Blasco I, Vinue A, Herrero-Cervera A et al (2016) Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/lymphotoxin β-receptor pathway. Thromb Haemost 116:379–393
26. Jin Y, Liu Y, Nelin LD (2015) Extracellular signal-regulated kinase mediates expression of arginase II but not inducible nitric-oxide synthase in lipopolysaccharide-stimulated macrophages. J Biol Chem 290:2099–2111
27. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795
28. Arakawa M, Mita T, Azuma K et al (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030–1037
29. ˗/˗ mouse model. Diab Vasc Dis Res 10:353–360
30. −/− mice. PLoS One 11:e0168396
31. Shiraki A, Oyama J, Komoda H et al (2012) The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221:375–382
32. Dai Y, Mehta JL, Chen M (2013) Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther 27:371–380
33. Krasner NM, Ido Y, Ruderman NB, Cacicedo JM (2014) Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One 9:e97554
34. Ridker PM, Luscher TF (2014) Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 35:1782–1791
35. Ussher JR, Drucker DJ (2014) Cardiovascular actions of incretin-based therapies. Circ Res 114:1788–1803
36. Stoger JL, Gijbels MJ, van der Velden S et al (2012) Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 225:461–468
37. Kim HS, Tavakoli S, Piefer LA, Nguyen HN, Asmis R (2016) Monocytic MKP-1 is a sensor of the metabolic environment and regulates function and phenotypic fate of monocyte-derived macrophages in atherosclerosis. Sci Rep 6:34223
38. Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M (2012) Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun 425:304–308
39. Zhuge F, Ni Y, Nagashimada M et al (2016) DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. Diabetes 65:2966–2979
40. Wang XP, Zhang W, Liu XQ et al (2014) Arginase I enhances atherosclerotic plaque stabilization by inhibiting inflammation and promoting smooth muscle cell proliferation. Eur Heart J 35:911–919